Fig. 1

Improvements in ultrasound (US) and magnetic resonance imaging (MRI) abnormalities during tocilizumab therapy. (1) US: coxofemoral effusion at baseline (a), week 2 (b), and week 12 (c). Synovitis with synovial hypertrophy (arrows) scored 3 at baseline, 2 at week 2, and 0 at week 12. (2) MRI: subacromial bursitis at baseline (d, score = 3), week 2 (e, score = 2), and week 12 (f, score = 0)